Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Non-Hodgkin Lymphoma Therapeutics Market

Non-Hodgkin Lymphoma Therapeutics Market Size

Report ID: GMI9696
Published Date: May 2024
Report Format: PDF

Download Free Sample

Non-Hodgkin Lymphoma Therapeutics Market Size

Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 9.5 billion in 2023 and is estimated to grow at 7.4% CAGR from 2024 to 2032. The market has experienced significant growth due to the increasing prevalence of Non-Hodgkin lymphoma worldwide.

To get key market trends

Download Free Sample

For instance, according to a study published by the American Society of Hematology in November 2022, approximately 779,000 new cases of Non-Hodgkin lymphoma are projected by 2040, marking a 43% increase from 2020. This growing burden of Non-Hodgkin lymphoma is anticipated to drive market growth. Additionally, the market is driven by a growing demand for cost-effective and accessible therapeutic solutions. Healthcare systems worldwide face the challenge of providing efficient oncology treatment within budget limitations. As a result, the escalating demand for treatments that offer both clinical efficacy and financial viability for patients drives further expansion in the market growth.

Non-Hodgkin lymphoma therapeutics refers to the range of medical treatments designed to manage and treat Non-Hodgkin lymphoma, a diverse group of blood cancers that originate in the lymphatic system. These therapies cover various approaches including chemotherapy, targeted therapy, radiation therapy, and stem cell transplantation.

Non-Hodgkin Lymphoma Therapeutics Market Report Attributes
Report Attribute	Details
Base Year:	2023
Non-Hodgkin Lymphoma Therapeutics Market Size in 2023:	USD 9.5 Billion
Forecast Period:	2024 – 2032
Forecast Period 2024 – 2032 CAGR:	7.4%
2024 – 2032 Value Projection:	USD 17.5 Billion
Historical Data for:	2021 – 2023
No. of Pages:	150
Tables, Charts & Figures:	306
Segments covered:	Type, Therapy Type, Gender, and Region
Growth Drivers:	Increasing incidence of Non-Hodgkin lymphoma Expanding investment and R&D activities Approval of new drugs and therapies
Pitfalls & Challenges:	High cost of treatment Stringent regulatory requirements

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Non-Hodgkin lymphoma therapeutics industry size was worth USD 9.5 billion in 2023 and is projected to expand at 7.4% CAGR from 2024 to 2032, due to the increasing prevalence of non-Hodgkin lymphoma worldwide.

The B-cell lymphomas type segment in the non-Hodgkin lymphoma therapeutics industry is estimated to record USD 9.6 billion by 2032, as these treatments enhance response rates and improve patient outcomes.

The radiation therapy segment in the non-Hodgkin lymphoma therapeutics industry accounted for 45.4% market share in 2023, due to the rising initiatives from key market players, including product launches and partnerships.

U.S. non-Hodgkin lymphoma therapeutics market recorded USD 3.9 billion in 2023 and is anticipated to grow at significant rate between 2024 and 2032, owing to the presence of advanced healthcare infrastructure, robust research and development environment, and substantial investments in cancer therapies.